Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System.
Prostate cancer
hypofractionated radiotherapy
radiotherapy
tracking
ultrasound
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
06
01
2021
revised:
17
03
2021
accepted:
25
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
The use of intra-fractional monitoring and correction of prostate position with the Image Guided Radio Therapy (IGRT) system can increase the spatial accuracy of dose delivery. Clarity is a system used for intrafraction prostate-motion management, it provides a real-time visualization of prostate with a transperineal ultrasound. The aim of this study was to evaluate the use of Clarity-IGRT on proper intrafraction alignment and monitoring, its impact on Planning Tumor Volume margin and on urinary and rectal toxicity in elderly patients not eligible for surgery. Twenty-five elderly prostate cancer patients, median age=75 years (range=75-90 years) were treated with Volumetric Radiotherapy and Clarity-IGRT using 3 different schemes: A) 64.5/72 Gray (Gy) in 30 fractions on prostate and seminal vesicles (6 patients); B) 35 Gy in 5 fractions on prostate and seminal vesicles (12 patients); C): 35 Gy in 5 fractions on prostate (7 patients). Ultrasound identification of the overlapped structures to the detected ones during simulation has been used in each session. A specific software calculates direction and entity of necessary shift to obtain the perfect match. The average misalignment in the three-dimensional space has been determined and shown in a box-plot. All patients completed treatment with mild-moderate toxicity. During treatment, genitourinary toxicity was 32% Grade 1; 4% Grade 2, rectal was 4% Grade 1. At follow-up of 3 months, genitourinary toxicity was 20% Grade 1; 4% Grade 2, rectal toxicity was 4% Grade 2. At follow-up of 6 months, genitourinary toxicity was 4% Grade 1; 4% Grade 2. Rectal toxicity was 4% Grade 2. Radiotherapy with the Clarity System allows a reduction of PTV margins, the amount of fractions can be reduced increasing the total dose, not exacerbating urinary and rectal toxicity with greater patient's compliance.
Sections du résumé
BACKGROUND
BACKGROUND
The use of intra-fractional monitoring and correction of prostate position with the Image Guided Radio Therapy (IGRT) system can increase the spatial accuracy of dose delivery. Clarity is a system used for intrafraction prostate-motion management, it provides a real-time visualization of prostate with a transperineal ultrasound. The aim of this study was to evaluate the use of Clarity-IGRT on proper intrafraction alignment and monitoring, its impact on Planning Tumor Volume margin and on urinary and rectal toxicity in elderly patients not eligible for surgery.
PATIENTS AND METHODS
METHODS
Twenty-five elderly prostate cancer patients, median age=75 years (range=75-90 years) were treated with Volumetric Radiotherapy and Clarity-IGRT using 3 different schemes: A) 64.5/72 Gray (Gy) in 30 fractions on prostate and seminal vesicles (6 patients); B) 35 Gy in 5 fractions on prostate and seminal vesicles (12 patients); C): 35 Gy in 5 fractions on prostate (7 patients). Ultrasound identification of the overlapped structures to the detected ones during simulation has been used in each session. A specific software calculates direction and entity of necessary shift to obtain the perfect match. The average misalignment in the three-dimensional space has been determined and shown in a box-plot.
RESULTS
RESULTS
All patients completed treatment with mild-moderate toxicity. During treatment, genitourinary toxicity was 32% Grade 1; 4% Grade 2, rectal was 4% Grade 1. At follow-up of 3 months, genitourinary toxicity was 20% Grade 1; 4% Grade 2, rectal toxicity was 4% Grade 2. At follow-up of 6 months, genitourinary toxicity was 4% Grade 1; 4% Grade 2. Rectal toxicity was 4% Grade 2.
CONCLUSION
CONCLUSIONS
Radiotherapy with the Clarity System allows a reduction of PTV margins, the amount of fractions can be reduced increasing the total dose, not exacerbating urinary and rectal toxicity with greater patient's compliance.
Identifiants
pubmed: 33910872
pii: 35/3/1849
doi: 10.21873/invivo.12447
pmc: PMC8193305
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1849-1856Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Phys Med Biol. 2015 Jan 21;60(2):549-63
pubmed: 25549204
Acta Oncol. 2012 Nov;51(8):963-74
pubmed: 22966812
BMC Cancer. 2016 Jul 15;16:484
pubmed: 27422044
Semin Radiat Oncol. 2014 Jul;24(3):196-9
pubmed: 24931092
Med Phys. 2016 Aug;43(8):4628
pubmed: 27487879
Clin Oncol (R Coll Radiol). 2015 May;27(5):270-9
pubmed: 25707911
BJU Int. 2013 May;111(5):761-6
pubmed: 23368740
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Radiother Oncol. 2016 Oct;121(1):103-108
pubmed: 27576431
Expert Rev Anticancer Ther. 2014 May;14(5):553-64
pubmed: 24579695
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):378-87
pubmed: 16563658
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e49
pubmed: 27448432
Technol Cancer Res Treat. 2010 Oct;9(5):433-52
pubmed: 20815415
Clin Oncol (R Coll Radiol). 2014 Apr;26(4):216-29
pubmed: 24529742
Eur Urol. 2015 Oct;68(4):683-91
pubmed: 25171903
Radiography (Lond). 2017 Nov;23(4):310-313
pubmed: 28965894
Cancer Treat Rev. 2016 Nov;50:48-60
pubmed: 27631875
Med Phys. 2013 Nov;40(11):111723
pubmed: 24320431
Cureus. 2015 Jun 20;7(6):e280
pubmed: 26180704
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1562-7
pubmed: 17056194
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1420-1429
pubmed: 30071296
Strahlenther Onkol. 2017 Mar;193(3):221-228
pubmed: 27928626
Radiother Oncol. 2013 Jan;106(1):50-8
pubmed: 23333022
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34
pubmed: 16690435
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):678-87
pubmed: 16751060
Technol Cancer Res Treat. 2017 Dec;16(6):1067-1078
pubmed: 29332454
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):182-95
pubmed: 25835624
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24
pubmed: 21324610
Phys Med. 2016 Mar;32(3):499-505
pubmed: 26851164
Phys Med Biol. 2015 Feb 7;60(3):R77-114
pubmed: 25592664
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9
pubmed: 22330997
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):361-373
pubmed: 29353654
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):195-201
pubmed: 20381268
Radiother Oncol. 2009 Mar;90(3):307-11
pubmed: 18952311
Radiother Oncol. 2008 Dec;89(3):304-10
pubmed: 18762347
Phys Med Biol. 2013 Apr 7;58(7):2413-27
pubmed: 23503362
Pract Radiat Oncol. 2017 Jan - Feb;7(1):e27-e33
pubmed: 27742558
Radiat Oncol. 2018 Aug 20;13(1):151
pubmed: 30126434
Radiother Oncol. 2007 Dec;85(3):418-23
pubmed: 18023491
In Vivo. 2020 Mar-Apr;34(2):757-765
pubmed: 32111781
Radiother Oncol. 2010 Feb;94(2):129-44
pubmed: 20153908
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):89-94
pubmed: 22652106
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):387-395
pubmed: 29534898
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1585-92
pubmed: 16863936
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):42-49
pubmed: 30611838